ArticleLife science alliance2023
SLAMF6 compartmentalization enhances T cell functions.
Article in Life science alliance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- SLAMF6 Enhances the Efficacy of Anti-PD-L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis.Cancer science · 2026Article
- Paradoxical Th1 activation and CTLA-4 regulation is beneficial during latent cryptococcosis.mBio · 2026Article
- Studying Macromolecular Composition in Cell-Cell Interfaces Using 3D Membrane Reconstitution Systems.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanisms of T cell activation: Integrating signaling pathways, experimental models, and therapeutic implications.EXCLI journal · 2026Review
- Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia.Nature cancer · 2025Article
- Causal effects and plasma protein mediators between type 2 diabetes and erectile dysfunction: a Mendelian randomization study.Sexual medicine · 2025Article
- Development and validation of an immune signature-based risk model for prognostic assessment in melanoma.Scientific reports · 2025Article
- SLAMF6 enables efficient attachment, synapse formation, and killing of HIV-1-infected CD4bioRxiv : the preprint server for biology · 2025Article
- Causal Characteristics of Immune Cells Associated with Aortic Dissection: A Mendelian Randomisation Analysis.European cardiology · 2025Article
- Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets.iScience · 2024Article
- Changing the location of proteins on the cell surface is a promising strategy for modulating T cell functions.Immunology · 2024Review
- Exclusion of PD-1 from the immune synapse: A novel strategy to modulate T cell function.Molecular therapy. Oncology · 2024Article
- SAP-expressing T peripheral helper cells identify systemic lupus erythematosus patients with lupus nephritis.Frontiers in immunology · 2024Article
- Study on gene expression in the liver at various developmental stages of human embryos.Frontiers in cell and developmental biology · 2024Article
- Genome-Wide Re-Sequencing Data Reveals the Population Structure and Selection Signatures of Tunchang Pigs in China.Animals : an open access journal from MDPI · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Signaling lymphocyte activation molecule family member 6 (SLAMF6) is a T cell co-receptor. Previously, we showed that SLAMF6 clustering was required for T cell activation. To better understand the relationship between SLAMF6 location and function and to evaluate the role of SLAMF6 as a therapeutic target, we investigated how its compartmentalization on the cell surface affects T cell functions. We used biochemical and co-culture assays to show that T cell activity is enhanced when SLAMF6 colocalizes with the CD3 complex. Mechanistically, co-immunoprecipitation analysis revealed the SLAMF6-interacting proteins to be those essential for signaling downstream of T cell receptor, suggesting the two receptors share downstream signaling pathways. Bispecific anti-CD3/SLAMF6 antibodies, designed to promote SLAMF6 clustering with CD3, enhanced T cell activation. Meanwhile, anti-CD45/SLAMF6 antibodies inhibited SLAMF6 clustering with T cell receptor, likely because of the steric hindrance, but nevertheless enhanced T cell activation. We conclude that SLAMF6 bispecific antibodies have a role in modulating T cell responses, and future work will evaluate the therapeutic potential in tumor models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.